期刊文献+

Microarray-based analysis for hepatocellular carcinoma: From gene expression profiling to new challenges 被引量:5

Microarray-based analysis for hepatocellular carcinoma:From gene expression profiling to new challenges
下载PDF
导出
摘要 Accumulation of mutations and alterations in the expression of various genes result in carcinogenesis,and the development of microarray technology has enabled us to identify the comprehensive gene expression alterations in oncogenesis.Many studies have applied this technology for hepatocellular carcinoma(HCC),and identified a number of candidate genes useful as biomarkers in cancer staging,prediction of recurrence and prognosis,and treatment selection.Some of these target molecules have been used to develop new serum diagnostic markers and therapeutic targets against HCC to benefit patients.Previously,we compared gene expression profiling data with classification based on clinicopathological features,such as hepatitis viral infection or liver cancer progression.The next era of gene expression analysis will require systematic integration of expression profiles with other types of biological information,such as genomic locus,gene function,and sequence information.We have reported integration between expression profiles and locus information,which is effective in detecting structural genomic abnormalities,such as chromosomal gains and losses,in which we showed that gene expression profiles are subject to chromosomal bias.Furthermore,array-based comparative genomic hybridization analysis and allelic dosage analysis using genotyping arrays for HCC were also reviewed,with comparison of conventional methods. Accumulation of mutations and alterations in the expression of various genes .result in carcinogenesis, and the development of microarray technology has enabled us to identify the comprehensive gene expression alterations in oncogenesis. Many studies have applied this technology for hepatocellular carcinoma (HCC), and identified a number of candidate genes useful as biomarkers in cancer staging, prediction of recurrence and prognosis, and treatment selection. Some of these target molecules have been used to develop new serum diagnostic markers and therapeutic targets against HCC to benefit patients. Previously, we compared gene expression profiling data with classification based on clinicopathological features, such as hepatitis viral infection or liver cancer .progression. The next era of gene expression analysis will require systematic integration of expression profiles with other types of biological information, such as genomic locus, gene function, and sequence information. We have reported integration between expression profiles and locus information, which is effective in detecting structural genomic abnormalities, such as chromosomal gains and losses, in which we showed that gene expression profiles are subject to chromosomal bias. Furthermore, arraybased comparative genomic hybridization analysis and allelic dosage analysis using genotyping arrays for HCC were also reviewed, with comparison of conventional methods.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2007年第10期1487-1492,共6页 世界胃肠病学杂志(英文版)
  • 相关文献

参考文献1

二级参考文献27

  • 1Fujimori M, Tokino T, Hino O, Kitagawa T, Imamura T,Okamoto E, Mitsunobu M, Ishikawa T, Nakagama H, Harada H. Allelotype study of primary hepatocellular carcinoma.Cancer Res 1991; 51:89-93.
  • 2Wang XW, Hussain SP, Huo TI, Wu CG, Forgues M, Hofseth LJ, Brechot C, Harris CC. Molecular pathogenesis of human hepatocelluar carcinoma. Toxicology 2002; 181-182:43-47.
  • 3Okada T, Iizuka N, Yamada-Okabe H, Mori N, Tamesa T,Takemoto N, Tangoku A, Hamada K, Nakayama H, Miyamoto T, Uchimura S, Hamamoto Y, Oka M. Gene expression profile linked to p53 status in hepatitis C virus-related hepatocellular carcinoma. FEBS Lett 2003; 555:583-590.
  • 4De Souza AT, Hankins GR, Washington MK, Orton TC,Jirtle RL. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995;11:447-449.
  • 5Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J,Gasser T, Mihatsch MJ, Kallioniemi OP, Sauter G. Highthroughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma.Am J Pathol 1999; 154:981-986.
  • 6Degot S, Regnier CH, Wendling C, Chenard MP, Rio MC,Tomasetto C. Metastatic Lymph Node 51, a novel nucleocytoplasmic protein overexpressed in breast cancer. Oncogene 2002; 21:4422-4434.
  • 7Yan HX, He YQ, Dong H, Zhang P, Zeng JZ, Cao HF, Wu MC,Wang HY. Physical and functional interaction between receptor-like protein tyrosine phosphatase PCP-2 and beta-catenin.Biochemistry 2002; 41:15854-15860.
  • 8Saad S, Gottlieb DJ, Bradstock KF, Overall CM, Bendall LJ.Cancer cell-associated fibronectin induces release of matrix metalloproteinase-2 from normal fibroblasts. Cancer Res 2002;62:283-289.
  • 9Koromilas AE, Roy S, Barber GN, Katze MG, Sonenberg N.Malignant transformation by a mutant of the IFN-inducibleds RNA-dependent protein kinase. Science 1992; 257:1685-1689.
  • 10Horiuchi K, Weskamp G, Lum L, Hammes HP, Cai H, Brodie TA, Ludwig T, Chiusaroli R, Baron R, Preissner KT, ManovaK, Blobel CP. Potential role for ADAM15 in pathologicalneovascul arization in mice. Mol Cell Biol 2003;23:5614-5624.

共引文献3

同被引文献20

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部